The story of the weight-loss drug market is one of the most celebrated in modern business: a scientific revolution that has turned Novo Nordisk into Europe’s most valuable company and made Eli Lilly a trillion-dollar titan. Two pharmaceutical giants, locked in a virtuous race to cure obesity and diabetes, enriching shareholders while saving lives. It is a narrative so compelling that even the lawsuits between them feel like a sign of healthy competition.
Then you read the complaint Novo Nordisk filed in New Jersey federal court 712. The Danish company is not suing over a patent infringement or a stolen trade secret. It is suing over an advertisement. Specifically, Lilly’s ads for Zepbound and Mounjaro, which Novo claims compare their drugs to Wegovy and Ozempic using “outdated” dosage data to make Lilly’s products look more effective 7. The allegation is that Lilly is not competing on science, but on a statistical sleight of hand.
Follow the contradiction. If both drugs are proven blockbusters with exploding demand, why would Lilly need to fudge a comparison? The answer lies in the incentives of a duopoly racing toward a patent cliff. Novo Nordisk’s semaglutide (Wegovy/Ozempic) faces generic competition in the next few years. Lilly’s tirzepatide (Zepbound/Mounjaro) is newer and has a longer runway. Every percentage point of market share captured today is a annuity that compounds for a decade. When the stakes are that high, the line between “competitive marketing” and “misleading the physician” becomes dangerously thin.
The accounting reality is that both companies are printing money, but the growth is increasingly expensive. Novo’s profit jump is real, but so is its spending on manufacturing capacity that may become obsolete. Lilly’s sales are surging, but its legal bills are rising. This lawsuit is not a distraction from the business; it is the business. In a market where the product is nearly identical and the customer (the doctor) is overwhelmed by data, the battlefield is perception.
Defenders of Lilly will argue that Novo is simply trying to stifle truthful comparative advertising, a standard tactic of a market leader protecting its turf. They will point out that Novo’s own studies have limitations, and that Lilly has a right to present its data. This is a valid point. But it misses the deeper issue: the reliance on a single, fragile metric—a clinical trial endpoint—to justify prices that can exceed $1,000 per month. If the comparison is misleading, the pricing is even harder to defend.